Navigation Links
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
Date:9/18/2008

-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, the company expects two additional microRNA diagnostic tests applying its technology will be validated and submitted for regulatory approval by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, including HIV, and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to obtain, maintain and protect its intellectual property; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's need and ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to su
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
2. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
3. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
4. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
10. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
11. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Bayer HealthCare ... Administration (FDA) has accepted the company,s Biologics License ... VIII compound.  Bayer is seeking FDA approval of ... the treatment of hemophilia A in children and ... continually bringing new therapies to hemophilia A patients ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... March 4, 2015 Sanomedics , ... a medical technology company that focuses on providing ... that the Company,s subsidiary, Thermomedics, Inc. , has ... and Government Sales. LeBel will be reporting to ... Sales, and will be responsible for supporting assigned ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 2Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 3
... , SAN MATEO, Calif., July 24 ... today the preliminary results of a short-term clinical study ... (PHN) following pretreatment with an FDA-approved topical anesthetic. As ... the U.S. Food and Drug Administration (FDA) requested the ...
... , , WISCONSIN ... of Wisconsin Cancer Center Riverview became the first medical facility ... of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, the ... cancer patients with the FDA-cleared Axxent(R) Electronic Brachytherapy System from ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:3/5/2015)... 2015 Hoggan Scientific, a ... physical therapy, ergonomic force gauges, and ergoPAK ... engineering, and research applications, introduced the ... at http://www.HogganHealth.net . The new electronic ... professionals a handgrip muscle strength testing device ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The Shaolin ... for Health and Wellness at Atlanta Shaolin Institute along ... 4350 Peachtree Industrial BLVD, Suite 500A, city of Peachtree ... Chan Foundation), which is a non-profit organization that promotes ... philosophy and medicine. , The seminar was well ...
(Date:3/4/2015)... Vegas, Nevada (PRWEB) March 04, 2015 ... is pleased to announce that they sell quality products ... Las Vegas, Nevada, this company obtains its merchandise from ... a known history of good performance. , Sleep apnea ... It is typically caused by reduced or restricted airflow. ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Imagine No Malaria’s ... the Care2 Innovator Award , an honor given to ... today at the Nonprofit Technology Conference (NTC15) in ... Tarrytown United Methodist Church in Austin, was on hand for ... for Imagine No Malaria. , Imagine No Malaria was one ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Ultraman Florida ... 6.2 mile swim, 261.4 mile bike, and 52.4 mile ... total time of 24:45:45. , "This race was awesome ... my wonderful team and sponsors for supporting me through ... Florida 2015 had a total of 40 select participants ...
Breaking Medicine News(10 mins):Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2
... today,announced that Noel Obourn, former chief sales officer ... president of financial,planning and analysis at Netflix, Inc., ... joins effective today as executive,vice president and head ... 18 and joins as senior vice president and ...
... for cross-border prevention, treatment programs , , WEDNESDAY, July 30 ... fourfold for male injection drug users who were deported ... in the Mexican border city, a new study reports. ... 5 at the International AIDS Conference in Mexico City, ...
... fat cells, may play a pivotal and counterintuitive role ... new study accepted for publication in the Journal ... people lose weight, the concentration level of adiponectin in ... has been associated with lower occurrence of diabetes and ...
... Premier Professional Online Medical Resource as ... ... Doctor,s Channel, (http://www.thedoctorschannel.com ), today announced the appointment of Jaime,Landman, ... Editor. Hailed by CNBC as the "educational,YouTube" for doctors, The ...
... STERIS Corporation,(NYSE: STE ) today announced financial ... 2008. Fiscal 2009 first quarter revenues increased,11% to $311.6 ... of,fiscal 2008, primarily driven by double digit revenue growth ... income was $25.5 million, or $0.43 per,diluted share, compared ...
... Unit-of-Use prescription compounding kits to its ... WOBURN, Mass., July 30 CutisPharma, ... prescription compounding, announced a,partnership with Rite Aid ... make its,innovative FIRST(R) Unit-of-Use Prescription Compounding Kits ...
Cached Medicine News:Health News:Extend Health, Inc. Adds Veteran Leadership to Management Team 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 2Health News:Deportation Tied to Higher HIV Risk for Men Injecting Drugs 3Health News:Protein made by fat cells may increase risk of heart attack in older adults 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 2Health News:The Doctor's Channel Adds Esteemed Director of Minimally Invasive Urology at Columbia University to Editorial Team 3Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 2Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 3Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 4Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 5Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 6Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 7Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 8Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 9Health News:STERIS Corporation Announces Fiscal 2009 First Quarter Results 10Health News:CutisPharma Announces Strategic Collaboration with Rite Aid Corporation 2Health News:CutisPharma Announces Strategic Collaboration with Rite Aid Corporation 3
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
... Simple, compact, and easy to use, the ... technology to every OR. The business model ... hospitals and surgeons with the most flexible ... facilities. ,The z-boxTM is designed to run ...
NOW Legionella is an immunochromatographic membrane assay to detect Legionella pneumophila serogroup 1 soluble antigen in human urine....
Medicine Products: